Scarica l'app Stockscreener
310.38
2.79%
-8.90
Dopo l'orario di chiusura:
310.38
Precedente Chiudi:
$319.28
Aprire:
$308.97
Volume 24 ore:
299.65K
Relative Volume:
0.60
Capitalizzazione di mercato:
$8.64B
Reddito:
$7.46M
Utile/perdita netta:
$-303.27M
Rapporto P/E:
-23.05
EPS:
-13.4668
Flusso di cassa netto:
$-249.12M
1 W Prestazione:
+2.54%
1M Prestazione:
-6.11%
6M Prestazione:
+462.38%
1 anno Prestazione:
+736.38%
Intervallo 1D:
$308.50
$321.94
Intervallo di 1 settimana:
$271.94
$338.31
Portata 52W:
$26.70
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
310.38 | 8.64B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-02 | Iniziato | Wells Fargo | Equal Weight |
| 2025-12-15 | Reiterato | Oppenheimer | Outperform |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine - Yahoo Finance
Aberdeen Group plc Takes $39.79 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
PRAX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
SG Americas Securities LLC Cuts Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
(PRAX) Risk Channels and Responsive Allocation - Stock Traders Daily
Praxis Precision Medicines, Inc. (PRAX) stock price, news, quote and history - Yahoo Finance UK
Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN
Praxis Precision Medicines announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Praxis Precision Medicines, Inc. (PRAX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
PRAX SEC FilingsPraxis Precision Medicines, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 13.4%Time to Buy? - MarketBeat
Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $525 - Moomoo
Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today? - MSN
PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
FDA Prioritizes Review of Praxis Precision's (PRAX) Drug Applica - GuruFocus
Praxis Precision Medicines Gets FDA Priority Review for Relutrigine - MarketScreener
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs - Bitget
FDA fast-tracks Praxis drug for rare childhood epilepsy disorders - Stock Titan
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vanguard subsidiaries disaggregate holdings; Praxis (PRAX) shows 0 shares reported - Stock Titan
Praxis Precision Medicines (NASDAQ:PRAX) Raised to Strong-Buy at Truist Financial - MarketBeat
(PRAX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings - AOL.com
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - AOL.com
Aug Swings: Is Praxis Precision Medicines Inc forming bullish engulfing patterns2026 Reactions & Reliable Momentum Entry Alerts - baoquankhu1.vn
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline - AOL.com
5AM Venture Divests Entire Praxis Precision Medicines Position | February 2026 FilingNews and Statistics - IndexBox
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit - AOL.com
Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization? - Yahoo Finance
Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway - Insider Monkey
PRAX PE Ratio & Valuation, Is PRAX Overvalued - Intellectia AI
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - AOL.com
Algert Global LLC Increases Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Cormorant Sells $9.31M in Praxis Shares, Holding Remains Top Position | 2026 UpdateNews and Statistics - IndexBox
This biotech stock, which has surged by 700%, remains one of the leading holdings even after a $9.3 million sale in the previous quarter. - Bitget
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool
HighVista Strategies LLC Has $5.04 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (PRAX) Is Down 5.4% After Major Institutional Buying and FDA FilingsHas The Bull Case Changed? - simplywall.st
Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? - Yahoo Finance
Praxis FDA Filings Shift Focus From Pipeline Promise To Potential Revenue - Yahoo Finance
PRAX Technical Analysis & Stock Price Forecast - Intellectia AI
Praxis Precision Medicines, Inc. $PRAX Shares Sold by B Group Inc. - MarketBeat
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year - AOL.com
A Look At Praxis Precision Medicines (PRAX) Valuation After New Driehaus Investment And Recent FDA Filings - simplywall.st
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):